Clinical Trials – October 21, 2026
Gesynta Pharma has completed enrollment in NOVA, its Phase II trial of the non-hormonal, non-opioid drug candidate vipoglanstat in endometriosis. The trial is fully enrolled more than three months ahead of schedule, and topline data are expected in the second quarter of 2027.
Clinical Trials – October 21, 2026
Finnish Faron Pharmaceuticals will present final survival data at ESMO 2026 from the melanoma cohort of its Phase 1/2 MATINS study. One in five patients achieved disease control on bexmarilimab alone, and these patients lived longer, although the difference was not statistically significant.
Column Iceland – October 20, 2026
If you know what an NMT phone is, or, even more so, if you’ve ever used one, it’s likely that you are formerly young. Slightly less so in Iceland, where well into the 2000s lots of the cool kids still had NMT phones in their jeeps. Your trusty Nokia 3310 could go several days on a charge, but drive away from a town or up a valley and the coverage quickly got spotty. With an NMT, though, you could head up toward the highlands or the upper reaches of a river and never be out of touch.
Clinical Trials – October 20, 2026
Danish allergy company ALK-Abelló reports that its house dust mite tablet Acarizax met the primary objective of a Phase 3 trial in China, with efficacy in line with earlier trials after only 24–28 weeks of treatment. ALK and its partner GenSci plan to file for approval in China in the first half of 2027.
Biotech Business – October 20, 2026
The US Food and Drug Administration (FDA) has approved a new manufacturing process for SIMLANDI, Alvotech’s biosimilar to Humira, that more than doubles drug substance output per batch at the company’s facility in Reykjavik.
Global report – October 20, 2026
The partnership aims to advance solutions to improve care pathways, clinical trial matching, safety monitoring, and guideline-directed care.
Clinical Trials – October 21, 2026
Gesynta Pharma has completed enrollment in NOVA, its Phase II trial of the non-hormonal, non-opioid drug candidate vipoglanstat in endometriosis. The trial is fully enrolled more than three months ahead of schedule, and topline data are expected in the second quarter of 2027.
Clinical Trials – October 21, 2026
Finnish Faron Pharmaceuticals will present final survival data at ESMO 2026 from the melanoma cohort of its Phase 1/2 MATINS study. One in five patients achieved disease control on bexmarilimab alone, and these patients lived longer, although the difference was not statistically significant.
Clinical Trials – October 20, 2026
Danish allergy company ALK-Abelló reports that its house dust mite tablet Acarizax met the primary objective of a Phase 3 trial in China, with efficacy in line with earlier trials after only 24–28 weeks of treatment. ALK and its partner GenSci plan to file for approval in China in the first half of 2027.
Clinical Trials – October 20, 2026
Zealand Pharma reports positive topline results from the multiple ascending dose part of its first-in-human Phase 1 trial of ZP9830, a Kv1.3 ion channel blocker being developed for autoimmune and inflammatory diseases.
Clinical Trials – October 19, 2026
Danish Evaxion reports that all patients in its Phase 2 trial of the personalized cancer vaccine EVX-01 in advanced melanoma kept their clinical responses at the three-year follow-up, with no tumor progression observed.
Clinical Trials – October 19, 2026
BioInvent has published results from the first clinical study of its anti-TNFR2 antibody BI-1808 in Clinical Cancer Research. In the Phase 1 dose escalation, no maximum tolerated dose was reached and all treatment-related side effects were grade 1 or 2.
Confidential
We are currently seeking a driven and relationship-oriented Key Account Manager in the Stockholm area.
PharmaRelations
PharmaRelations is looking for a Head of Regulatory Affairs Development to lead and further develop our Regulatory Affairs services in the drug development space.
PharmaRelations
PharmaRelations is now looking for a Head of Clinical Operations in Denmark who wants to continue to build and develop our business in Denmark and south of Sweden (Öresundsregionen).
Confidential
PharmaRelations is recruiting a Medical Device Auditor, on behalf of an innovative and fast-growing organization operating at the intersection of medical technology, regulatory compliance, and advanced digital solutions.
Karl Storz Endoskop Sverige AB
KARL STORZ är ett tyskt medicintekniskt företag som specialiserar sig på tillverkning och försäljning av endoskopisk utrustning och kirurgiska instrument. Företaget grundades 1945 i Tuttlingen av Dr. Karl Storz och har en lång historia av innovation inom medicinsk teknik.
PharmaRelations
You will have the opportunity to work in a team of PV specialists, helping our clients with the best solutions depending on their needs.
In a new job – October 19, 2026
Lars Fruergaard Jørgensen, who led Novo from 2017 to 2025, is set to become Chair of the Board of Lundbeck. He will join the board as an observer on November 10, 2026, and the board intends to appoint him Chair after the company’s 2027 Annual General Meeting.
In a new job – October 13, 2026
Eric Honroth is stepping down as President Life Science and member of the Executive Team at Swedish medtech company Getinge to take on an external role.
In a new job – October 9, 2026
Rolf Sass Sørensen succeeds co-founder Martin Rose. Founders Martin Rose and Jesper Breum move on to pursue new biotech ventures while remaining shareholders in the company.
Career choice – September 14, 2026
From Stanford’s sunlit engineering quad to SciLifeLab’s brisk knowledge hub in Stockholm, Emma Lundberg works across two distinct innovation cultures. She sees lessons for Sweden in Silicon Valley’s close links between academia, investors, and industry, but also strengths at home that should not be lost.
Careers article – August 14, 2026
Returning to work after a long, relaxing vacation can be challenging. Here are some tips to make the transition easier and less stressful.
Careers article – July 19, 2026
Thomas Karikari’s career has taken him across three continents: from Ghana to the UK and Sweden, and then to the US. Now an Associate Professor at the University of Pittsburgh and one of Nature Index’s “rising stars in ageing research”, he is helping move Alzheimer’s blood biomarkers beyond individual markers and towards a more complete picture of disease biology.
Profiles in Business – October 18, 2026
Sesselja Ómarsdóttir has spent her career moving between academia and industry, from lichen chemistry in an Icelandic lab to leading Genis today. She talks about mentorship, curiosity, and what it means to keep one foot in each world.
Profiles in Business – October 12, 2026
Finnish Heidi Haikala has a foot in two life science worlds. As a cancer researcher she has established her own research group at the University of Helsinki and Tampere University, and she is also a co-founder of the startup company Solid IO.
Profiles in Business – October 4, 2026
Unbeknownst to her, Jessica Martinsson’s long and varied career in research and life sciences was preparing her for her newest and possibly most influential role.
Global report – October 20, 2026
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended EU approval of Eli Lilly’s Foundayo (orforglipron), a once-daily GLP-1 tablet for weight management and type 2 diabetes in adults. If approved, it will compete with Novo’s Wegovy pill in Europe.
Pharma Business – October 19, 2026
Danish Ascendis Pharma has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP), recommending EU approval of once-weekly TransCon CNP (navepegritide) for children with achondroplasia.
Pharma article – October 19, 2026
Norwegian microbiome diagnostics company Genetic Analysis is presenting results today at UEG Week 2026 in Barcelona on GA-map IBD Precision Dx, a test designed to identify, at diagnosis, which ulcerative colitis patients are at risk of an aggressive disease course.
MedTech Business – October 15, 2026
UK digital pathology provider Diagnexia has signed an agreement to use Swedish medical imaging IT company Sectra’s cloud-based Image Exchange Portal to receive, send and report on pathology cases from NHS organizations.
MedTech Business – October 14, 2026
SciBase has secured its first positive US medical policy from a major Blue Cross Blue Shield organization: Highmark will cover the company’s Nevisense skin lesion assessment for patients being evaluated for possible melanoma.
MedTech Business – October 14, 2026
Swedish medtech company NanoEcho has been declared bankrupt after failing to find a solution to its strained financial situation.
Biotech Business – October 14, 2026
Alvotech and its partner Advanz Pharma have submitted a European regulatory application for AVT29, a proposed biosimilar to the high-dose retinal disease drug Eylea 8 mg. According to the companies, it is the first known submission of its kind worldwide.
Biotech article – October 13, 2026
The Drug Discovery and Development (DDD) platform at SciLifeLab has completed the first GMP-compatible cell line developed within BRIDGE Sweden, a national initiative to strengthen Sweden’s capacity for biologics development. The top-performing clones produce more than seven grams of monoclonal antibody per liter.
Biotech Business – October 12, 2026
Health Canada has approved Camurus’s Oczyesa XR, a once-monthly subcutaneous octreotide depot, for maintenance treatment of adults with acromegaly who have responded to and tolerated treatment with somatostatin analogs.
Science News – October 14, 2026
Women vaccinated against HPV before their first pregnancy were less likely to give birth prematurely, according to a Swedish register study from Karolinska Institutet published in The BMJ.
Funding – October 13, 2026
The Knut and Alice Wallenberg Foundation is granting SEK 900 million to thirty research projects that international experts have judged to be groundbreaking and at the forefront of global research. Ten of the projects are in medicine, spanning cancer, immunology, hearing restoration, and fibromyalgia.
Science News – October 13, 2026
Joakim Lundeberg, Professor of Molecular Biotechnology at KTH Royal Institute of Technology, has received the 2026 Gold Medal from the Royal Swedish Academy of Engineering Sciences (IVA) for developing spatial transcriptomics, a method now used in life science research worldwide.
This site uses cookies
